Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

There Is Potential in This Highly Lucrative Industry: Gilead Sciences, Inc. (GILD), Bristol Myers Squibb Co. (BMY), Johnson & Johnson (JNJ)

Gilead Sciences, Inc. (NASDAQ:GILD) is the world’s foremost biopharmaceutical company when it comes to combating deadly virus. It is far ahead of competitors in the field of HIV and hepatitis treatment. Gilead is the only company with an FDA approved AIDS prevention therapy. The governing body has approved Gilead’s Truvada for people in the high risk aids profession such as caretakers of infected personal and nursing staff. The company is already the global leader in HIV treatment due to high sales of Truvada and Atripla.

According to recent reports doctors have finally been able to cure an infant from HIV. The patient was given a drug cocktail 30 hours after birth to suppress the virus. This could be a breakthrough in the fight against AIDS as this is the first time a newborn has been cured from the disease. The reports also indicate that the patient has been virus free for the last 10 months. According to Bloomberg, approximately 300,000 children are infected yearly, with a large number in developing countries.

Gilead Sciences, Inc. (NASDAQ:GILD)AIDS Drug Market

Gilead is currently the leader in the AIDS treatment industry with Truvada and Atripla. Atripla had sales of $3.2 billion in 2011, and Truvada generated sales of $2.8 billion. Truvada is a combination of Gilead Sciences, Inc. (NASDAQ:GILD) drugs Viread and Emtriva. The company has recently received FDA approval for its drug Stibild, which is a combination of four different drugs. Bristol Myers Squibb Co. (NYSE:BMY) is just behind Gilead in this industry with Reyataz and Sustiva generating annual sales of approximately $1.5 billion and $1.4 billion respectively.

Merck is also a serious contender in this industry with Isentress, which generates approximately $1.1 billion in sales. Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE) are lagging far behind with their drugs Intelence and Selzentry.


Although a number of breakthroughs have been made in the fight against AIDS, the pursuit of complete HIV eradiation is still ongoing. According to reports, a number of companies are trying find a permanent cure for the virus with Gilead Sciences, Inc. (NASDAQ:GILD), J&J and Merck leading the quest.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.